Federated Hermes’s Aegerion Pharmaceuticals AEGR Stock Holding History

Federated Hermes’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-110,280	Closed	-$328K	–	2249
2016 Q3	$328K	Sell	110,280 -131,117	-54%	-$227K	﹤0.01%	1394
2016 Q2	$360K	Buy	241,397 +127,591	+112%	+$292K	﹤0.01%	1358
2016 Q1	$421K	Buy	113,806 +73,181	+180%	+$453K	﹤0.01%	1326
2015 Q4	$410K	Buy	+40,625	New	+$489K	﹤0.01%	1343
2014 Q2	–	Sell	-108,000	Closed	-$4.98M	–	2040
2014 Q1	$4.98M	Sell	108,000 -25,468	-19%	-$1.49M	0.02%	638
2013 Q4	$9.47M	Sell	133,468 -32,562	-20%	-$2.49M	0.03%	463
2013 Q3	$14.2M	Sell	166,030 -50,470	-23%	-$4.28M	0.05%	293
2013 Q2	$13.7M	Buy	+216,500	New	+$11.5M	0.05%	276

Federated Hermes's AEGR Position: Q4 2016 in Review

Federated Hermes sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 110,280 shares — an estimated $328K sold.

Federated Hermes first reported a position in AEGR in Q2 2013 and held it in 8 quarters. The position peaked at $14.2M in Q3 2013. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.

Federated Hermes reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Federated Hermes sold 110,280 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $328K.
Federated Hermes first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 8 quarters.
Federated Hermes's Aegerion Pharmaceuticals position peaked at $14.2M in Q3 2013.
0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.

Based on Federated Hermes's 13F filing for Q4 2016, filed 10 Feb 2017.